核糖体生物发生率,对抑制rRNA合成的化疗药物敏感性的参数
Davide Treré1,2, Lorenzo Montanaro1,2, Massimo Derenzini3
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Oncology reviews
|February 9, 2026
概括
针对核糖体生物生成 (RiBi) 的癌症化疗药物通过抑制MDM2.2来起作用. 高水平的RiBi增强了药物的有效性,而低水平或突变可能需要组合疗法来有效地杀死癌细胞.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 许多癌症化疗药物通过抑制核糖体生物发生 (RiBi) 起作用.
- 抑制RiBi导致核糖体蛋白结合和中和MDM2 (小鼠双分钟2),这是细胞增殖和细胞亡的关键调节者.
- RiBi 抑制剂的疗效受癌细胞的 RiBi 速率和核糖体蛋白 (RP) 基因组状态的影响.
研究的目的:
- 审查和讨论RiBi速率和RP突变/删除如何影响RiBi抑制剂在癌细胞中的MDM2抑制.
- 基于细胞特征,探索克服对RiBi抑制剂耐药性的策略.
- 强调评估RiBi速率和RP状态对于预测治疗反应的重要性.
主要方法:
- 文献审查和现有研究结果的讨论.
- 分析RiBi速率,RP突变/删除和MDM2抑制之间的关系.
- 对不同癌细胞环境 (例如,p53状态) 的治疗策略的检查.
主要成果:
- 高的RiBi速率与增加的核糖体蛋白释放,强大的MDM2抑制和RiBi抑制剂治疗后的亡诱导相关.
- 相反,低的RiBi率或RP突变/删除的存在可能导致MDM2抑制不足,从而导致癌细胞抵抗.
- 在p53野生型细胞中,将RiBi抑制剂与p53稳定药物结合起来,可以克服耐药性.
- 在p53缺乏的癌症中,添加MDM2抑制剂是一种潜在的治疗方法.
结论:
- 在癌症组织中评估RiBi速率和RP突变/删除状态对于预测对RiBi抑制剂的敏感性至关重要.
- 这种评估可以指导选择更合适和更有效的治疗方案.
- 基于这些生物标志物的个性化治疗策略可能会改善癌症化疗的结果.
相关概念视频
Ribosomal RNA Synthesis
14.9K
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
14.9K
Ribosomal RNA Synthesis
4.4K
4.4K
Ribosomes
76.7K
Ribosomes translate genetic information encoded by messenger RNA (mRNA) into proteins. Both prokaryotic and eukaryotic cells have ribosomes. Cells that synthesize large quantities of protein—such as secretory cells in the human pancreas—can contain millions of ribosomes.
Ribosome Structure and Assembly
Ribosomes are composed of ribosomal RNA (rRNA) and proteins. In eukaryotes, rRNA is transcribed from genes in the nucleolus—a part of the nucleus that specializes in ribosome...
Ribosome Structure and Assembly
Ribosomes are composed of ribosomal RNA (rRNA) and proteins. In eukaryotes, rRNA is transcribed from genes in the nucleolus—a part of the nucleus that specializes in ribosome...
76.7K
Ribosomes
11.0K
Ribosomes translate genetic information encoded by messenger RNA (mRNA) into proteins. Both prokaryotic and eukaryotic cells have ribosomes. Cells that synthesize large quantities of protein—such as secretory cells in the human pancreas—can contain millions of ribosomes.
Ribosome Structure and Assembly
Ribosomes are composed of ribosomal RNA (rRNA) and proteins. In eukaryotes, rRNA is transcribed from genes in the nucleolus—a part of the nucleus that specializes in ribosome...
Ribosome Structure and Assembly
Ribosomes are composed of ribosomal RNA (rRNA) and proteins. In eukaryotes, rRNA is transcribed from genes in the nucleolus—a part of the nucleus that specializes in ribosome...
11.0K
Drugs Affecting Neurotransmitter Synthesis
2.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.2K
Factors Influencing Drug Absorption: Anatomical Parameters
642
Drug absorption involves the movement of drugs from the point of administration into the systemic circulation. Initially, Gastrointestinal (GI) motility propels the drug through the digestive tract and into the stomach. However, the stomach's high acidity and limited surface area restrict its role in drug absorption for most drugs. The drug then moves from the stomach to the small intestine via gastric emptying, which can be slowed by various factors, including interactions with other...
642


